Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Nucleic Acids Research
|
July 2, 2015
The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function
Claire Breslin, Peter Hornyak, Andrew Ridley, et al.
DNA Repair
|
November 1, 2015
Versatility in phospho-dependent molecular recognition of the XRCC1 and XRCC4 DNA-damage scaffolds by aprataxin-family FHA domains
Amy L Cherry, Timothy J Nott, Geoffrey Kelly, et al.
The EMBO Journal
|
November 27, 2012
APLF promotes the assembly and activity of non-homologous end joining protein complexes
Gabrielle J Grundy, Stuart L Rulten, Zhihong Zeng, et al.
Neurobiology of Disease
|
October 12, 2004
Shortfalls in the peptidyl-prolyl cis-trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias
Julian R Thorpe, Sabrina Mosaheb, Lida Hashemzadeh-Bonehi, et al.
Nature Communications
|
April 12, 2016
The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins
Gabrielle J Grundy, Stuart L Rulten, Raquel Arribas-Bosacoma, et al.
Nucleic Acids Research
|
September 20, 2013
PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage
Stuart L Rulten, Amy Rotheray, Ryan L Green, et al.
Molecular Cell
|
January 8, 2011
PARP-3 and APLF function together to accelerate nonhomologous end-joining
Stuart L Rulten, Anna E O Fisher, Isabelle Robert, et al.
Nature Communications
|
August 18, 2016
PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2)
Gabrielle J Grundy, Luis M Polo, Zhihong Zeng, et al.
Nature
|
December 22, 2016
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia
Nicolas C Hoch, Hana Hanzlikova, Stuart L Rulten, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Nucleic Acids Research
|
July 2, 2015
The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function
Claire Breslin, Peter Hornyak, Andrew Ridley, et al.
DNA Repair
|
November 1, 2015
Versatility in phospho-dependent molecular recognition of the XRCC1 and XRCC4 DNA-damage scaffolds by aprataxin-family FHA domains
Amy L Cherry, Timothy J Nott, Geoffrey Kelly, et al.
The EMBO Journal
|
November 27, 2012
APLF promotes the assembly and activity of non-homologous end joining protein complexes
Gabrielle J Grundy, Stuart L Rulten, Zhihong Zeng, et al.
Neurobiology of Disease
|
October 12, 2004
Shortfalls in the peptidyl-prolyl cis-trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias
Julian R Thorpe, Sabrina Mosaheb, Lida Hashemzadeh-Bonehi, et al.
Nature Communications
|
April 12, 2016
The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins
Gabrielle J Grundy, Stuart L Rulten, Raquel Arribas-Bosacoma, et al.
Nucleic Acids Research
|
September 20, 2013
PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage
Stuart L Rulten, Amy Rotheray, Ryan L Green, et al.
Molecular Cell
|
January 8, 2011
PARP-3 and APLF function together to accelerate nonhomologous end-joining
Stuart L Rulten, Anna E O Fisher, Isabelle Robert, et al.
Nature Communications
|
August 18, 2016
PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2)
Gabrielle J Grundy, Luis M Polo, Zhihong Zeng, et al.
Nature
|
December 22, 2016
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia
Nicolas C Hoch, Hana Hanzlikova, Stuart L Rulten, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Page
of 3